Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.

You may also be interested in...



Novartis To Make Its Medical Education Programs Virtual Under DOJ Settlement

Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.

Kickback Suit Against Novartis Can Proceed, Judge Says

Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.

Third Strike For Novartis: DOJ Alleges Firm Paid Kickbacks To Specialty Pharmacies

Government has intervened in a whistleblower suit alleging Novartis provided financial incentives to CVS Caremark and other specialty pharmacies to get them to recommend Exjade, Gleevec, and other Novartis drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel